Dragon Jade International, LTD v. Ultroid, LLC

CourtDistrict Court, M.D. Florida
DecidedSeptember 29, 2020
Docket8:17-cv-02422
StatusUnknown

This text of Dragon Jade International, LTD v. Ultroid, LLC (Dragon Jade International, LTD v. Ultroid, LLC) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dragon Jade International, LTD v. Ultroid, LLC, (M.D. Fla. 2020).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION

DRAGON JADE INTERNATIONAL, LTD.,

Plaintiff/Counter-Defendant,

v. Case No: 8:17-cv-2422-T-27CPT

ULTROID, LLC, ULTROID MARKETING DEVELOPMENT CORP., and ULTROID TECHNOLOGIES, INC.,

Defendants/Counter-Plaintiffs. ___________________________________/

ORDER

BEFORE THE COURT is Plaintiff/Counter-Defendant’s “Motion for Partial Summary Judgment on Ultroid’s Counterclaims” (Dkt. 176), and Defendants/Counter-Plaintiffs’ response (Dkt. 177). Upon consideration, the motion is GRANTED in part and DENIED in part. I. BACKGROUND Dragon Jade International, Ltd. (“Dragon Jade”) brought this action alleging that Ultroid, LLC, Ultroid Marketing Development Corp., and Ultroid Technologies, Inc. (collectively, “Ultroid”), breached two agreements between the parties. See (Dkts. 1, 1-1, 1-2). Ultroid counterclaimed, alleging a violation of the Florida Deceptive and Unfair Trade Practices Act (Counterclaim I), violations of the federal and Florida Racketeering Influenced and Corrupt Organization Acts (Counterclaims II and III), rescission of the Option Agreement (Counterclaim IV), rescission of the Option and Security Agreements (Counterclaim V), fraud in the inducement – rescission (Counterclaim VI), conspiracy to defraud (Counterclaim VII), and breach of contract (Counterclaim VIII). (Dkt. 126). Counterclaims II-IV were previously dismissed. (Dkt. 136). Dragon Jade now moves for summary judgment on four of Ultroid’s five remaining counterclaims. (Dkt. 176). II. UNDISPUTED MATERIAL FACTS Dragon Jade is a “life science company” that “is focused on identifying, developing and marketing new technologies including therapeutics, medical devices and nutritional supplements.” (Dkt. 12-1 ¶¶ 1, 2). Its principal place of business is Hong Kong, China. (Dkt. 1 at 3, ¶ 7). Ultroid is the manufacturer of a Hemorrhoid Management System (the “Device”), which is comprised of a base unit and single-use probe kit that is intended for non-anesthetic, rapid coagulative homeostatic therapy of internal hemorrhoids.1 (Dkt. 12-1 ¶¶ 3, 4). Ultroid’s principal place of

business is Tampa, Florida. (Dkt. 1 at 4, ¶¶ 8-10). Sometime around June 2015, Dragon Jade’s Chief Executive Officer, Dr. Steve Lai, became interested in the Device and requested to meet with Ultroid representatives. (Dkt. 126 ¶ 16; Dkt. 139 ¶ 15; Dkt. 169 at p. 6:8-9). In June 2015, Ultroid’s founder, Michael Cao, visited Hong Kong to meet with Dr. Lai. (Dkt. 126 ¶ 16; Dkt. 139 ¶ 16). On June 29, 2015, the parties entered into an International Distribution Agreement whereby they agreed that Dragon Jade would be the exclusive distributor of the Device throughout China. (Dkt. 139 ¶ 19; Dkt. 12-1 ¶ 3). Soon after the agreement was signed, Dragon Jade placed its first order. (Dkt. 12-1 ¶ 6). However, on August 27, 2015, the FDA issued a warning letter to Ultroid regarding deficiencies with its quality management system (“QMS”) and internal control structures for the Device.2 (Dkt. 20-1 ¶ 5; Dkt.

1 The Device was developed in the early 2000s by an electrical engineer and gastroenterologist. (Dkt. 126 ¶ 2). In 2003, the Food and Drug Administration (“FDA”) granted the developer a 510(k) premarketing authorization, which approved the Device to be manufactured and placed on the market. (Id. ¶ 3). Once the Device was offered on the open market, Ultroid purchased the Device, including its intellectual property. (Id. ¶ 4). 2 When Dragon Jade learned of the FDA warning letter is in dispute. See (Dkt. 12-1 ¶ 7; Dkt. 176-3 at p. 176-2 at 2-6). As a result, Ultroid spent the remainder of 2015 and early 2016 working to remediate its QMS to satisfy the FDA’s concerns. (Dkt. 169-3 at p. 65:1-22). Around the time the warning letter was issued, Dragon Jade expressed an interest in acquiring Ultroid. (Dkt. 126 ¶ 20; Dkt. 139 ¶ 20). In November 2015, Cao and Michael Knox, Ultroid’s then-Chief Executive Officer, traveled to Hong Kong to meet with Dr. Lai. (Dkt. 169-5 at pp. 13:1-5, 13:24-14:1). Following that meeting, Ultroid hired a private company to conduct a valuation report of its worth, and in February 2016, Ultroid was appraised at $84,000,000. (Dkt. 176-4 at 3). Also in February 2016, and while Ultroid was still working to remediate its QMS, Knox

became ill and was placed in a medically induced coma for six days, and hospitalized for three weeks. (Dkt. 176-5 at pp. 35:9-36:1-21; Dkt. 20-1 ¶ 6). While Knox was ill and in recovery, Cao assumed the role of acting CEO and took control of Ultroid. (Id.). Dragon Jade became aware of Knox’s health issues. (Dkt. 177-5 at 5). In April 2016, Knox and Cao traveled to China to meet Dr. Lai and discuss Dragon Jade’s purchase of Ultroid. (Dkt. 20-1 ¶ 7; Dkt. 169-3 at pp. 122:18-20, 123:10-13). Knox and Cao were handed envelopes of cash to reimburse them for the cost of their flights. (Dkt. 169-5 at p. 14:2-7). During this trip, Dragon Jade offered $40,000,000 to purchase Ultroid. (Dkt. 177-2 at pp. 9:25-10:1-7). According to Dr. Lai, Knox first proposed to work for Dragon Jade during this trip. (Dkt. 169-5 at p. 39:3-9). In July 2016, the FDA conducted an annual inspection of Ultroid’s QMS. (Dkt. 169-6 at p.

65:19-21). According to Knox, “[i]t was not a favorable review,” and involved the same issues as

293:2-7). the prior FDA warning. (Dkt. 169-3 at p. 94:8-16). In September 2016, Ultroid issued a voluntary recall of the Device and suspended manufacturing until the FDA’s concerns were addressed.3 (Dkt. 20-1 ¶ 8). As a result of the recall, acquisition negotiations between Ultroid and Dragon Jade ceased and Ultroid proposed instead that Dragon Jade purchase its assets.4 (Dkt. 176-13 at 3). Asset purchase negotiations soon began between the parties. (Dkt. 20-1 ¶ 9). In October 2016, Knox emailed Dr. Lai and Dragon Jade’s consultant, Glenn Henricksen, to inform them that Cao had resigned from the Board and that Knox “was given formal authority, by the board to finalize the terms for the asset sale to [Dragon Jade], and was instructed to accomplish this as quickly as possible.” (Dkt. 176-8 at 2). One month later, Henricksen informed Knox that Dragon

Jade was offering $3,000,000 to purchase Ultroid’s Device. (Dkt. 12-1 ¶ 24; Dkt. 176-7 at 1-3). That offer was rejected. (Dkt. 12-1 ¶ 24; Dkt. 169-2 at p. 114:12-14). Notwithstanding, in December 2016, the parties resumed asset sale negotiations, and on December 28, 2016, Knox advised Ultroid’s Board of Directors that Dragon Jade was still interested in the “Ultroid Brand.” (Dkt. 176-13 at 5). After a vote, the Board authorized Knox to “begin formal discussions with [Dragon Jade] for the purpose to sell the assets of [Ultroid].” (Id.). On January 3, 2017, Dragon Jade initiated an arbitration proceeding against Ultroid. (Dkt. 12-1 ¶ 25). According to Dragon Jade, arbitration was initiated because Ultroid could not deliver the Device in accordance with the parties’ International Distribution Agreement. (Dkt. 169-2 at pp. 83:14-20, 84:6-15). Notwithstanding, asset negotiations resumed, and on January 11, 2017,

3 Prior to the recall, Knox resigned from his “C-level and managerial positions” with Ultroid due to family concerns. (Dkt. 176-5 at pp. 88:3-11, 89:16-90:1-3; Dkt. 177 at 4). He remained employed by Ultroid and continued to serve as director, secretary, and treasurer until he was terminated in February 2018. (Id.; Dkt. 176-10). 4 The assets include the 510(k) premarketing authorization, US Patent Nos. 8131380 and 9179966, CA Patent No. 2597892, and US Registered Trademark Nos. 3526435 and 1485175. (Dkt. 176-15 at 9; Dkt. 177-6 ¶ 3). Henricksen, on behalf of Dragon Jade, presented verbal terms of a proposed asset sale to Ultroid’s Board.5 (Dkt. 12-1 ¶ 26; Dkt. 176-13 at 7).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Restigouche, Inc. v. Town of Jupiter
59 F.3d 1208 (Eleventh Circuit, 1995)
Allen v. Tyson Foods, Inc.
121 F.3d 642 (Eleventh Circuit, 1997)
Hickson Corp. v. Northern Crossarm Co.
357 F.3d 1256 (Eleventh Circuit, 2004)
Baxter v. Palmigiano
425 U.S. 308 (Supreme Court, 1976)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Masson v. New Yorker Magazine, Inc.
501 U.S. 496 (Supreme Court, 1991)
Scott v. Harris
550 U.S. 372 (Supreme Court, 2007)
Kernel Records Oy v. Timothy Z. Mosley
694 F.3d 1294 (Eleventh Circuit, 2012)
Dolphin LLC v. WCI Communities, Inc.
715 F.3d 1243 (Eleventh Circuit, 2013)
Walters v. Blankenship
931 So. 2d 137 (District Court of Appeal of Florida, 2006)
D & M JUPITER, INC. v. Friedopfer
853 So. 2d 485 (District Court of Appeal of Florida, 2003)
Rollins, Inc. v. Butland
951 So. 2d 860 (District Court of Appeal of Florida, 2006)
Noack v. Blue Cross and Blue Shield
742 So. 2d 433 (District Court of Appeal of Florida, 1999)
Crown Ice MacHine Leas. Co. v. Sam Senter Farms, Inc.
174 So. 2d 614 (District Court of Appeal of Florida, 1965)
Securities & Exchange Commission v. Scherm
854 F. Supp. 900 (N.D. Georgia, 1993)
Rodriguez v. Recovery Performance & Marine, LLC
38 So. 3d 178 (District Court of Appeal of Florida, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
Dragon Jade International, LTD v. Ultroid, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dragon-jade-international-ltd-v-ultroid-llc-flmd-2020.